Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Rhea-AI Summary

Prelude Therapeutics (Nasdaq: PRLD), a precision oncology company, announced that CEO Kris Vaddi, PhD, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference in Miami, FL, on March 17, 2022, at 9:00 a.m. ET. A live webcast will be available on the company's website under the 'Investors' page. Prelude Therapeutics is focused on developing innovative drug candidates targeting critical cancer cell pathways, with a diverse pipeline including four clinical candidates and two preclinical ones aimed at addressing underserved cancer patients.

WILMINGTON, Del., March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference in Miami, FL on Thursday, March 17, 2022 at 9:00 a.m. ET.

A live webcast of the fireside chat can be accessed by visiting the “Investors” page under the “Events & Presentation” section of the Prelude website, where a replay will be available for a limited time.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients.  Prelude’s pipeline includes four candidates currently in clinical development: PRT543 and PRT811, highly selective, potent, orally bioavailable PRMT5 inhibitors; PRT1419, a potent, selective inhibitor of MCL1; and PRT2527, a potent and highly selective CDK9 inhibitor.  Additionally, the Company is progressing two novel preclinical candidates, PRT3645, a brain penetrant CDK4/6 inhibitor; and a potential first-in-class SMARCA2/BRM protein degrader. 

Investor Contacts:
Stacey Jurchison
Executive Director, Corporate Affairs
sjurchison@preludetx.com

Melissa Forst
Argot Partners
212.600.1902
prelude@argotpartners.com

Media Contact:
Paige Donnelly
Argot Partners
212.600.1902
prelude@argotpartners.com

FAQ

What is the date and time of the Prelude Therapeutics fireside chat at Barclays 2022 Global Healthcare Conference?

The fireside chat is scheduled for March 17, 2022, at 9:00 a.m. ET.

How can I access the webcast of the Prelude Therapeutics conference presentation?

You can access the live webcast on the 'Investors' page of the Prelude Therapeutics website.

What is Prelude Therapeutics focused on developing?

Prelude Therapeutics develops innovative drug candidates targeting critical cancer cell pathways.

What are the key candidates in Prelude Therapeutics' pipeline?

Key candidates include PRT543, PRT811, PRT1419, and PRT2527.

Where is Prelude Therapeutics headquartered?

Prelude Therapeutics is headquartered in Wilmington, Delaware.